Johnson & Johnson Completes Acquisition of V‑Wave Ltd.

Johnson & Johnson Acquires Shockwave Medical

April 5, 2024

Medical Devices

Johnson & Johnson will acquire Shockwave Medical for $335.00 per share in an all-cash transaction valued at approximately $13.1 billion including cash acquired. The deal adds Shockwave’s intravascular lithotripsy (IVL) technology to Johnson & Johnson MedTech, expanding J&J’s cardiovascular intervention portfolio and accelerating growth in high‑growth CAD and PAD markets.

Johnson & Johnson Acquires Abiomed

December 22, 2022

Medical Devices

Johnson & Johnson completed its acquisition of Abiomed on December 22, 2022, acquiring all outstanding shares for $380.00 per share (approximately $16.6 billion enterprise value) plus a contingent value right. Abiomed will operate as a standalone business within Johnson & Johnson's MedTech segment, expanding J&J's capabilities in high-growth cardiovascular and heart-recovery solutions.

Shockwave Medical Acquires Neovasc

January 17, 2023

Medical Devices

Shockwave Medical, a U.S.-based cardiovascular device company, agreed to acquire Canada-based Neovasc for approximately $100 million upfront plus a contingent value right of up to $12 per share tied to regulatory milestones. The acquisition adds the Neovasc Reducer System for refractory angina to Shockwave’s cardiology portfolio and is expected to close subject to customary conditions and shareholder approval.

JLL Partners Invests in Vascular Technology, Incorporated

June 30, 2025

Medical Devices

JLL Partners, a New York-based middle market private equity firm, has announced an investment in Vascular Technology, Incorporated (VTI), a Nashua, New Hampshire-based medical device company that develops intraoperative Doppler systems and remote suction/irrigation solutions. As part of the transaction JLL partnered with entrepreneur Nilendu Srivastava and the VTI management team and appointed Greg Groenke as CEO and Lars Marcher as Executive Chairman to accelerate product development and market expansion.

Johnson & Johnson MedTech Acquires Laminar, Inc.

November 30, 2023

Medical Devices

Johnson & Johnson MedTech has completed the acquisition of Laminar, Inc., a privately held medical device developer focused on eliminating the left atrial appendage (LAA) in patients with non‑valvular atrial fibrillation, for $400 million upfront plus potential clinical and regulatory milestone payments. Laminar will join Johnson & Johnson MedTech’s Biosense Webster business to expand the company’s electrophysiology and interventional cardiology portfolio and accelerate development and commercialization of Laminar’s rotational LAA elimination technology.

Edwards Lifesciences Acquires JenaValve and Endotronix to Expand Structural Heart and Heart Failure Portfolio

July 24, 2024

Medical Devices

Edwards Lifesciences has entered agreements to acquire JenaValve Technology and Endotronix for an aggregate upfront purchase price of approximately $1.2 billion. The transactions expand Edwards' structural heart portfolio into aortic regurgitation and heart failure management, complementing its existing valve franchise and remote hemodynamic monitoring capabilities.